ANIX (Anixa Biosciences) OCF Margin %: 0.00% (As of Apr. 2026)


ANIX Anixa Biosciences Inc ANIX
27 GF Score
Price $2.40
! 3 Warning Signs
View Full Analysis

What is Anixa Biosciences OCF Margin %?

Anixa Biosciences ANIX -8.92% 27 OCF Margin % is 0.00% as of Apr. 2026. GuruFocus rates ANIX with a GF Score™ of 27/100. The stock has 3 warning signs investors should review. Among 959 Biotechnology companies, Anixa Biosciences ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Anixa Biosciences's Cash Flow from Operations for the three months ended in Apr. 2026 was $-1.74 Mil. Anixa Biosciences's Revenue for the three months ended in Apr. 2026 was $0.00 Mil. Therefore, Anixa Biosciences's OCF Margin % for the quarter that ended in Apr. 2026 was 0.00%.

As of today, Anixa Biosciences's current OCF Yield % is -8.72%.

The historical rank and industry rank for Anixa Biosciences's OCF Margin % or its related term are showing as below:


During the past 13 years, the highest OCF Margin % of Anixa Biosciences was -383.92%. The lowest was -2956.67%. And the median was -1086.67%.

ANIX's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Anixa Biosciences OCF Margin % Related Terms

Anixa Biosciences OCF Margin % Historical Data

* Premium members only.

The historical data trend for Anixa Biosciences's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anixa Biosciences OCF Margin % Chart

Anixa Biosciences Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -964.45 0.00 -2,956.67 0.00 0.00

Anixa Biosciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ANIX
27GF Score
Anixa Biosciences Inc ANIX
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anixa Biosciences OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Anixa Biosciences's OCF Margin for the fiscal year that ended in Oct. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Oct. 2025 )/Revenue (A: Oct. 2025 )
=-7.173/0
= %

Anixa Biosciences's OCF Margin for the quarter that ended in Apr. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Apr. 2026 )/Revenue (Q: Apr. 2026 )
=-1.741/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Anixa Biosciences (ANIX) has a OCF Margin % of 0.00% as of Apr. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Anixa Biosciences and its competitors. According to the industry distribution chart, Anixa Biosciences ranks #999999 out of 959 companies in the Biotechnology industry.
Is Anixa Biosciences' OCF Margin % too high?
Anixa Biosciences' current OCF Margin % is 0.00%. Based on the distribution chart, Anixa Biosciences ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Anixa Biosciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Anixa Biosciences' OCF Margin % compare to PYPD and LONA?
According to the Biotechnology industry distribution chart, Anixa Biosciences ranks #999999 out of 959 companies for OCF Margin %. This places Anixa Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Anixa Biosciences and its competitors. Anixa Biosciences's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anixa Biosciences stock overvalued right now?
Anixa Biosciences (ANIX) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Anixa Biosciences' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Anixa Biosciences (ANIX), the current OCF Margin % is 0.00% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anixa Biosciences Business Description

Other Exchanges CY71:Germany
Address 3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
27GF Score

Get the complete analysis for ANIX

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.40
Price